Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
NCT06401824
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
25
Enrollment
OTHER
Sponsor class
Conditions
NSCLC Stage IV
Brain Metastases, Adult
Interventions
DRUG:
Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab
Sponsor
Maastricht University Medical Center
Collaborators
[object Object]